Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia

Hematol Oncol Clin North Am. 1990 Apr;4(2):389-404.

Abstract

Philadelphia chromosome (Ph)-negative chronic myelogenous leukemia (CML) and chronic myelomonocytic leukemia (CMML) are heterogeneous disorders characterized by various degrees of proliferation, dysplasia, maturation arrest, and monocytosis. In this article, the clinical, laboratory, molecular, and therapeutic aspects of the disease entities are reviewed.

Publication types

  • Review

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Bone Marrow Transplantation
  • Cohort Studies
  • Combined Modality Therapy
  • Female
  • Humans
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative* / blood
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative* / epidemiology
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative* / etiology
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative* / physiopathology
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative* / therapy
  • Leukemia, Myelomonocytic, Chronic* / blood
  • Leukemia, Myelomonocytic, Chronic* / etiology
  • Leukemia, Myelomonocytic, Chronic* / physiopathology
  • Leukemia, Myelomonocytic, Chronic* / therapy
  • Male
  • Middle Aged
  • Oncogenes
  • Prognosis
  • Risk Factors

Substances

  • Antineoplastic Agents